Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Speckle Tracking Ekkokardiografi som et værktøj til tidlig diagnose af nedsat fostervækst tvillingegraviditeter (HEART)

16. september 2026 opdateret af: University Hospital, Ghent

Speckle Tracking Ekkokardiografi som et værktøj til tidlig diagnose af nedsat fostervækst i tvillingegraviditeter

In this project there are 2 time points during the pregnancy included, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 21 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Fetal growth restriction (FGR) is diagnosed in 5-10% of the pregnancies. After preterm birth, it is the second leading cause of perinatal morbidity and mortality. Twin pregnancies have a higher occurrence of FGR than singletons, in monochorionic (MC) twin pregnancies it's diagnosed in 19.7% of the cases and in dichorionic (DC) twin pregnancies in 10.5% of the cases. Fetuses with FGR are at greater risk of perinatal morbidity and mortality and even long-term health defects. From a public health perspective, it's important to correctly diagnose FGR to adjust the antenatal and postnatal care and to have more insight into the factors influencing early onset cardiovascular disease. STE has a strong predictive value for cardiovascular function, therefore it would be a promising tool to add in the routine pregnancy clinical care. Speckle tracking echocardiography (STE) is a relative new technique especially in the pregnancy follow up, which permits offline calculation of myocardial velocities and deformation parameters. These parameters, including strain and strain rate, provide information about the fetal myocardial function. Apart from investigating if STE can be used for the prediction of FGR, we will also investigate the association between fetal exposure to air pollution and in utero cardiac remodeling. Indeed, it is known that inhalation of particulate matter (e.g. black carbon) during the pregnancy can reach the placenta and lead to alterations in the placenta's function including increases in oxidative stress markers. Early life exposure to black carbon has been associated with adverse cardiovascular health outcomes and reduction of fetal growth, especially in multiple gestation pregnancies.

In this project we will include 2 time points during the pregnancy, namely at 21 weeks and 30 weeks of gestation, to measure the predictive values of FGR, strain and strain rate. The fetal growth parameters will be collected at the same time points, to define the growth (differences) throughout gestation of both fetuses. A maternal blood sample will be taken at 20 weeks of gestation to identify the level of exposure to air pollution (black carbon) and the level of biochemical markers of placental dysfunction. Doppler ultrasounds will be used for antenatal identification of placenta insufficiency. At birth, umbilical cord blood and the placenta will be collected. The placenta will be examined, to identify morphological findings which are associated with FGR. The umbilical cord blood and placental biopsy will be used for the level of exposure to air pollution and the level of oxidative stress. One to three days after birth, neonatal strain and strain rate will be measured to define postnatal cardiac remodeling as well as the neonatal blood pressure as cardiovascular risk factor.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

360

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Ghent, Belgien, 9000
        • Rekruttering
        • Ghent University Hospital
        • Kontakt:
          • Kristien Roelens, prof. dr.
      • Leuven, Belgien, 3000
        • Ikke rekrutterer endnu
        • Universitair ziekenhuis Leuven
        • Kontakt:
          • Liebeth Lewie, prof. dr.
      • Eindhoven, Holland, 5631
        • Ikke rekrutterer endnu
        • Maxima medical center
        • Kontakt:
          • Judith van Laar, dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 45 år (Voksen)

Tager imod sunde frivillige

N/A

Køn, der er berettiget til at studere

Kvinde

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

The number of subjects that will be included in this study is: 600 neonates (200 twin pairs and 200 singletons) and 400 pregnant mothers.

The fetuses are divided into following sub-groups:

  • Appropriately grown
  • Fetal growth restricted
  • Selective fetal growth restricted (specific for twins)

Beskrivelse

Inclusion Criteria:

  • Singleton or dichorionic twin pregnancy
  • Pregnant women 21 weeks ( ± 2 weeks) of gestation at the first visit
  • Women ≥ 18 years

Exclusion Criteria:

  • Women pregnant of multiples of higher order (≥3 siblings) Monochorionic twin pregnancy
  • Fetal arrhythmia
  • Known fetal congenital or genetic abnormalities
  • Any suspicion of congenital fetal anomalies that might influence fetal cardiac function
  • Pre-existing maternal hypertensive disease
  • Autoimmune disease including systemic lupus erythematosus
  • History of stillbirth
  • Diabetes mellitus (mother)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Fetal growth restricted

Observation of cardiac remodeling perinatal and postnatal

blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

Appropriately grown

Observation of cardiac remodeling perinatal and postnatal

blood sample at 21 weeks of gestation clips of the fetal heart at 21 weeks of gestation, 30 weeks of gestation and 1-3 days after birth collection of umbilical cord blood at birth collection of the placenta at birth

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To assess the change in strain measured by speckle tracking echocardiography as a tool for early diagnosis of impaired fetal growth in multiple gestations
Tidsramme: Prenatal to 1-3 days after birth

to determine the change in fetal strain and strain rate in twin pregnancies in comparison with fetal growth

Prenatal to 1-3 days after birth
To determine the intra-pair differences in fetal growth and strain (cardiac remodeling) in multiple gestations.
Tidsramme: Prenatal to 1-3 days after birth

to compare changes in strain and strain rate with fetal growth within 1 twin pair

Prenatal to 1-3 days after birth
To compare the strain values (cardiac remodeling) between singletons and twin pregnancies
Tidsramme: Prenatal to 1-3 days after birth

to compare the changes in strain and strain rate between singletons and twin pregnancies

Prenatal to 1-3 days after birth

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To investigate the association between placenta functioning and in utero cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth

to evaluate placenta insufficiency (Doppler ultrasound, biochemical marker) with strain and strain rate

Prenatal to 1-3 days after birth
To explore in utero cardiac remodeling in association with neonatal cardiovascular health
Tidsramme: Prenatal to 1-3 days after birth

to evaluate strain and strain rate with the neonatale blood pressure and heart rate

Prenatal to 1-3 days after birth
To study the association between prenatal air pollution exposure and in utero cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth

to evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with strain and strain rate

Prenatal to 1-3 days after birth
To investigate placenta functioning as a mediator between air pollution and cardiac remodeling
Tidsramme: Prenatal to 1-3 days after birth

To evaluate prenatal air pollution (black carbon particles in blood sample mother and placenta) with placenta insufficiency (biochemical marker, Doppler ultrasound)

Prenatal to 1-3 days after birth

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Kristien Roelens, University Hospital, Ghent

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. juni 2023

Primær færdiggørelse (Anslået)

1. februar 2027

Studieafslutning (Anslået)

1. februar 2028

Datoer for studieregistrering

Først indsendt

31. maj 2022

Først indsendt, der opfyldte QC-kriterier

14. juni 2022

Først opslået (Faktiske)

21. juni 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

16. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • ONZ-2022-0193

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .